November 27, 2009 (FinancialWire) Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, has received 510(k) clearance from the FDA to update its package insert for its Verigene(R) Respiratory Virus Nucleic Acid Test on Verigene SP System (RVNATSP) to include reactivity with Influenza A in cultured clinical isolates containing 2009 H1N1 influenza virus.
Nanosphere confirmed through analytical reactivity testing that their RVNATSP assay correctly identifies Influenza A in cultured clinical isolates containing 2009 H1N1. The RVNATSP assay was cleared by the FDA in October 2009, for the differential diagnosis of Influenza A, Influenza B, and RSV infections. Although the RVNATSP has been shown to detect the 2009 H1N1 influenza virus in cultured isolates, the performance characteristics of this device with patient specimens that are positive for the 2009 H1N1 influenza virus have not been established. The RVNATSP can distinguish between Influenza A and B viruses, but it does not differentiate influenza subtypes. For further discussion of the performance characteristics of the assay, please refer to the Verigene(R) Respiratory Virus Nucleic Acid Test on Verigene SP System (RVNATSP) package insert.
The RVNATSP incorporates viral RNA extraction and isolation, RT-PCR amplification, and multiplexed detection in a fully automated system that requires only a single pipetting step. The automated Verigene SP System provides sample-to-result molecular diagnostics capabilities in a multiplexed, random-access, modular system utilizing the same imaging technology as the first generation Verigene, allowing for complementary or stand alone integration into both molecular and microbiology laboratories.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).
Quidel Issues Clarification Regarding Special 510(k) Clearance to Add 2009 H1N1 Influenza A Virus Reactivity Information to .. Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, issues clarification regarding the Special 510(k) clearance for an update to the Company's QuickVue® Influenza... |
QIAGEN Releases New Pandemic Influenza A/H1N1 Detection Kit QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA), today announced both the launch of a new Influenza A/H1N1 test and several updates to its activities in providing solutions for the global surveillance... |
Studies Confirm that Arch Chemicals’ Vantocil™ FHC Antimicrobial Product Is Effective Against Swine Flu Virus Arch Chemicals, Inc. announced today that research has demonstrated that its Vantocil™ FHC antimicrobial product, which has long been used in hygiene applications in Europe and other global regions,... |
TechnoVax Receives $2.9 Million Grant for Flu and Influenza Virus-Like Particle (VLP) Vaccine Program TechnoVax, Inc., a biotechnology developer of novel vaccines was awarded a three-year $2.9 million SBIR phase II grant from the National Institutes of Health to further the development of its VLP-based,... |
Cat confirmed to have swine flu A cat in Iowa has reportedly been confirmed to be infected with the H1N1 virus. Des Moines, Iowa (WiredPRNews.com) The first known case of a feline being infected with the swine flu virus has been reported.... |
Adamis Pharmaceuticals’ Patented Vaccine Technology Induces Broad Immunity Against Influenza Virus Adamis Pharmaceuticals Corporation : http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fadamispharmaceuticals.com%2F&esheet=6018703&lan=en_US&anchor=Adamis+Pharmaceuticals+Corporation&index=1... |
